Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? Authors: Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Séamus O’Reilly Published: 2026 ABSTRACT The introduction of biologics marked a paradigm shift in the treatment of numerous life threatening and life limiting diseases such as cancer. Addressing cost effectiveness in medical oncology is necessary as cancer cases are expected to increase globally by nearly 60% in the next decade which will place an increasing demand on effective drug options. Biologic drugs carry a significant financial burden which could be alleviated with the increased use of biosimilars without compromising on quality, safety, or efficacy. Global spending on cancer drugs is expected to rise from $223 billion in 2023 to $409 billion in 2028 which is largely driven by the authorisation of novel biologic drugs. The cost of cancer drugs in Irish hospitals surged from €4.7 million in 2013 to €151 million in 2022—a gain exceeding 3,100%. The Irish Health Service Executive reported a low uptake of biosimilars with usage varying widely between hospitals. Barriers to the use of biosimilars included resistance to substitution at the community pharmacy level, and introduction of subcutaneous biologics that extend patent protection. In conclusion there remains significant potential to improve biosimilar adoption rates in Ireland which would allow both increased patient access and treatment equity. Thus, this commentary explores the use of biosimilars to address this financial burden in medical oncology and increase access to biologic cancer drugs. Introduction The introduction of biologics marked a paradigm shift in the treatment of numerous life-limiting and life-threatening conditions, including rheumatologic, neurological and oncological diseases1. Biologics, defined as “pharmaceutical compounds derived or synthesised from biological sources” [1], have delivered substantial therapeutic benefits but remain prohibitively expensive, limiting patient access [2–4]. This is particularly evident in health systems where reimbursement is influenced by private insurance status [2–4]. As biologics represent the fastest-growing class of medicines and global cancer incidence is projected to increase by nearly 60% in the coming decade, addressing costs in oncology is an international priority [5]. Biosimilars-"biological medicines highly similar to an already approved reference product”-have comparable structure, biological activity, efficacy, safety and immunogenicity to their reference biologics [6]. Multiple systematic reviews and meta-analyses have subsequently confirmed that biosimilars achieve comparable effectiveness, safety and immunogenicity to their reference biologics across a wide range of therapeutic areas, including oncology. Furthermore, there is no evidence of reduced efficacy following switching from an originator biologic to a biosimilar [7, 8]. Biosimilars are generally less costly, enabling more sustainable drug spending and improved accessibility [9]. Internationally, healthcare systems are increasingly relying on biosimilars as a strategy to improve the sustainability of cancer care while maintaining equitable patient access to biologic therapies [10–15]. Recent evidence from Europe, Latin America and international oncology organisations demonstrates that successful biosimilar implementation depends not only on regulatory approval but also on supportive procurement policies, clinician confidence and patient engagement [10–15]. By 2020, biosimilar uptake had already saved EU healthcare systems over €10 billion [16], yet remain the largest category of medicines expenditure within the Irish Health Service Executive (HSE) [17]. This commentary examines the global and national landscape of oncology biologics, the role of biosimilars in improving cost-effectiveness, and the challenges limiting their optimal use in Ireland. While biosimilars now comprise 52–54% of oncology biologics in Ireland, uptake remains well below that of countries such as Austria, the Netherlands and Norway, where it exceeds 90% [18]. These countries have combined national procurement strategies, coordinated tendering systems, financial incentives, clinician education and clear implementation policies, demonstrating that health-system factors are major determinants of successful biosimilar adoption [18–22]. Thus, we outline barriers to adoption in Ireland and discuss potential strategies to optimise patient access to these valuable medicines. Access to oncology biologics internationally Biologics contribute disproportionately to rising global medicines expenditure, outpacing growth in other healthcare costs [10]. The global oncology landscape is characterised by rapidly increasing expenditure alongside an expanding pipeline of innovative therapies [23, 24]. IQVIA estimates that global oncology medicine spending will increase from US$252 billion in 2024 to approximately US$441 billion by 2029, while highlighting that biosimilar competition for high-cost biologics will be an important mechanism for improving healthcare sustainability and moderating expenditure growth [23, 24]. These findings further support international efforts to optimise biosimilar uptake as a means of improving access to innovative cancer therapies while maintaining equitable and financially sustainable oncology services [24]. This growth compels payers and health technology assessment (HTA) agencies to prioritise treatments based on value and cost-effectiveness [10, 23, 24]. By 2029, the number of biologics reaching the end of their patent, and thus exclusivity phase, will triple compared with 2021, representing an estimated €9 billion in market value [20]. Key oncology biologics, including Opdivo® (nivolumab) and Keytruda® (pembrolizumab), are expected to lose European patent protection in 2030 and 2031 respectively [25]. Variations in supplementary protection certificates-including pending applications in Ireland-may influence the timing of biosimilar availability [25]. Experience from Latin America demonstrates that biosimilars can support healthcare sustainability by expanding access to biologic therapies without compromising financial viability [11]. However, inconsistent policy, fragmented procurement, and originator-driven market strategies can limit their uptake, highlighting the importance of coordinated national approaches that are directly relevant to the Irish context [11]. Regulatory processes are evolving, with the Medicines and Healthcare products Regulatory Agency pioneering biosimilar approval based on pharmacokinetic bridging studies, and the European Medicines Agency considering a similar streamlined approach relying more on analytical and pharmacokinetic data [11]. Alongside regulatory changes, European hospitals—including those in Ireland—procure biologics and biosimilars mainly through tendering systems [12, 20]. Evidence suggests multi-winner tenders are more cost-effective than single-winner approaches and support a more competitive, sustainable market helping to reduce prices and encourage biosimilar uptake [20, 21]. These international developments provide an important context for Ireland, where increasing expenditure on biologic therapies has intensified the need to maximise the value derived from biosimilars while ensuring sustainable access to innovative oncology treatments. Cost implications of biologics in Ireland Against this international backdrop, spending on novel cancer drugs, including biologics, accounts for an increasingly significant share of Ireland's healthcare budget [26]. The cost of hospital-administered cancer medicines—rising from approximately €4.7 million in 2013 to €151 million in 2022 and €187 million in 2023—reflects expenditure captured under the Oncology Drug Management Scheme (ODMS), which reimburses centrally funded high-cost oncology medicines [27]. However, this underestimates total hospital spending, as drugs approved prior to 2012, including some biologics such as trastuzumab (Herceptin®), remain funded through hospital base budgets [26, 27]. Meanwhile, community expenditure on high-tech medicines (including oncology drugs) reached €1,146.6 million in 2023 [28, 29]. Biosimilars as a means of addressing the financial burden in oncology Ensuring equitable access to innovation is now recognised as a central challenge in contemporary oncology [13, 22, 30]. Biosimilars offer a pragmatic mechanism to reconcile innovation with access by releasing resources that can be reinvested into novel therapies [13, 22, 30]. The next five years represent a pivotal period for biosimilar adoption in oncology, with several high-cost biologics approaching patent expiry and biosimilar entry expected to increase across international markets. Increased market competition has the potential to reduce treatment costs, improve healthcare system sustainability and expand patient access to biologic therapies that may previously have been restricted because of financial constraints [10, 11, 13, 20, 22, 25, 31–34]. Beyond cost savings, earlier availability of affordable biologic treatments may facilitate more equitable access to innovative therapies, reduce delays in treatment initiation and allow healthcare systems to reinvest savings into novel cancer medicines and supportive care services [10, 11, 13, 20, 22, 25, 31–34]. However, realising these patient benefits depends on timely market entry, competitive procurement processes, supportive reimbursement policies and clinician and patient confidence in biosimilar use [10, 11, 13, 20, 22, 25, 31–34].Across Europe, biologics account for more than 30% of total drug spending, yet biosimilars comprise only 1.5% of this share [22]. Uptake has steadily increased since 2014, and by 2018, biosimilars competed with 16 originator biologics representing 21% of total biologic spending (€12 billion) [22]. In Ireland, biosimilar uptake varies widely across hospitals, ranging from 0 to 100% [17]. The HSE’s Best-Value Biologic (BVB) programme—initially focused on tumour necrosis factor (TNF)-α inhibitors and now extended to agents such as granulocyte colony-stimulating factor (G-CSF)—aims to promote biosimilar prescribing [28, 29, 35]. The Medicines Management Programme supports this through prescriber guidance and patient information, achieving €22.7 million in savings in its first year [28, 29, 35].While the average annual treatment cost for conditions such as rheumatoid arthritis (€12,700 per patient) has begun to fall with biosimilar adoption, cancer therapy costs (€13,500 per patient annually) continue to rise [28, 29, 35]. Under the 2021 Framework Agreement, existing pegfilgrastim biosimilars were priced at 55% of the originator’s July 2016 price, and new biosimilars at no more than 55% of the originator’s October 2021 price [29]. Despite this, as of January 2024, Neulasta® and the widely used biosimilar Pelgraz® remain similarly priced [29], limiting expected savings. Updated commercial submissions reviewed by the Medicines Management Programme suggest further efficiencies could be achieved through better identification and prescribing of Best-Value Biologic medicines [29]. Barriers and facilitators to biosimilar use in Ireland Legal and intellectual property strategies employed by originator companies further complicate biosimilar uptake [36]. Practices such as patent thickets, strategic litigation, and minor formulation changes can function as forms of intellectual property (IP) abuse, delaying biosimilar market entry without corresponding clinical benefit [36]. Despite approval pathways from the European Medicines Agency supporting interchangeability, Ireland’s Health (Pricing and Supply of Medical Goods) Act 2013 excludes biosimilars from the list of interchangeable medicines. As a result, automatic pharmacy substitution is not permitted, and clinicians must actively switch patients [14, 31]. Pharmacists in Ireland cannot substitute unless explicitly indicated on the prescription, despite guidance from the American Society of Clinical Oncology supporting interchangeable use [15]. International experience demonstrates that high biosimilar uptake can be achieved through different policy mechanisms rather than through one single model. France has introduced pharmacy-level biosimilar substitution within defined biological medicine groups, while Germany is moving further towards mandatory pharmacy substitution of eligible biologics under specified criteria from April 2026. In contrast, countries such as Norway, Denmark and the Netherlands have largely achieved high biosimilar uptake through coordinated procurement, tendering, prescribing guidance and stakeholder engagement, while Belgium illustrates the challenges of improving uptake in the absence of a structured national switching or substitution framework [1, 7, 14, 31, 37]. Even so, biosimilars in Ireland generate annual savings exceeding €80 million [38]. However, they account for only 52–54% of the oncology biologics market, compared with over 90% in countries such as Austria and Netherlands, indicating significant room for further savings [22]. Although these international experiences demonstrate the potential benefits of high biosimilar uptake, direct extrapolation to Ireland should be interpreted with caution because uptake is influenced by medicine-specific patent expiry, pricing, tendering arrangements, reimbursement policies, clinician acceptance and national substitution legislation. Consequently, these examples are presented to illustrate potential policy approaches rather than expected Irish market shares. Recent international policy initiatives increasingly advocate coordinated procurement, clinician education, transparent switching policies and routine monitoring of biosimilar uptake. Countries achieving uptake rates exceeding 90% have generally combined financial incentives with national implementation strategies, suggesting that policy interventions, rather than clinical concerns alone, are major determinants of successful biosimilar adoption [10, 12, 15, 20, 21]. Resistance to biosimilar substitution persists. One Irish study found patients were generally more open to switching than prescribers, and medical students more open than qualified doctors [39]. This suggests that clinician perceptions and concerns about interchangeability and substitution may contribute to ongoing hesitation [40, 41]. Subcutaneous (SC) biologics like trastuzumab and rituximab extend patent protections, delaying biosimilar adoption and cost savings due to their higher price (e.g., SC Herceptin® at €1,200 versus IV biosimilar at €400) [42]. While SC options enhance patient quality of life, reduce hospital time, and support community-based care, their cost creates a trade-off between service efficiency and affordability [42]. They also reduce IV-related waste, contributing to sustainability goals [42, 43]. Addressing these challenges requires a coordinated implementation strategy encompassing procurement, reimbursement, clinician engagement and legislative reform. This should include competitive multi-winner tendering, consideration of pharmacist-supported biosimilar substitution where appropriate, national prescribing guidance, and ongoing education to address concerns regarding biosimilar interchangeability. Together, these measures could facilitate earlier biosimilar uptake, increase competition following patent expiry, and enable reinvestment of savings into innovative cancer medicines and patient-centred oncology services [12, 13, 15, 20–22, 34, 45]. Furthermore, successful drugs are frequently protected by a large number of often-overlapping patents, known as a patent thicket [44]. These patent portfolios make it difficult for generics or biosimilars to enter the market and can extend market exclusivity periods [45]. Lowering healthcare expenditure on biologics, and reallocating the savings to improve access to these therapies, is critical for ensuring equitable treatment availability. Expanding access can reduce long-term complications by enabling more patients to receive timely treatment, ultimately benefiting the overall health economy [34]. Optimising biosimilar use aligns closely with the emerging concept of pharmacoequity—the principle that all patients should have access to the highest-quality treatments regardless of socioeconomic or geographic factors [45]. For sustainable and equitable access, policymakers must prioritise strategies that maximize value for money. These could include leveraging biosimilars, optimising drug schedules and dosing, reducing wastage, utilising expanded access programs and clinical trials, and, where appropriate, avoiding unnecessary treatments [34]. Identified barriers and facilitators are included in Fig. 1.Fig.1Barriers and faciliators to biosimilar uptake in Ireland Barriers and faciliators to biosimilar uptake in Ireland Analysing the cost of leakage / wastage of biologics Globally, medicine leakage and drug wastage represent major drivers of rising oncology costs, with cancer drug wastage in the United States (US) alone estimated at approximately US $779 million in 2021 [46]. A 2024 review in the Irish Journal of Medical Science similarly identified drug wastage as a key opportunity for optimising oncology expenditure, though quantitative Irish estimates remain limited [35]. In response to the medication landscape above, Ireland’s Medicines Sustainability Taskforce is undertaking a comprehensive evaluation of medicines expenditure across care settings to better understand cost drivers and biosimilar utilisation [47]. As part of this work, the Biosimilars Subgroup plans to introduce two key performance indicators—an 80% uptake targe BVBs in both community and acute hospital settings—to promote more efficient biologic use and support long-term system sustainability [47]. Together, these developments provide a timely opportunity to critically assess biosimilar adoption, reduce unnecessary wastage, and enhance both market access and patient outcomes. Conclusion The Irish experience reflects wider international challenges in translating regulatory approval of biosimilars into routine clinical practice. Across Europe, healthcare systems are increasingly recognising biosimilars as a key strategy for improving the sustainability of oncology services while expanding equitable access to innovative biologic therapies [10, 11, 13, 20–22, 30–34]. Evidence from high-performing healthcare systems demonstrates that coordinated national policies, competitive procurement processes, clinician and patient engagement, and transparent switching frameworks can substantially increase biosimilar uptake while maintaining clinician confidence and patient trust [10, 11, 13, 20–22, 30–34]. International policy guidance further emphasises that sustainable biosimilar markets require consistent reimbursement strategies, stakeholder collaboration and long-term investment in implementation rather than relying solely on regulatory approval [10, 11, 13, 20–22, 30–34]. These experiences provide valuable lessons for Ireland as it seeks to optimise biosimilar utilisation, improve pharmacoequity and maximise the reinvestment of savings into innovative cancer treatments [10, 11, 13, 20–22, 30–34]. The rising costs of biologics and their critical role in oncology care highlight the urgent need to optimise their use. Biosimilars offer a cost-effective solution while maintaining high standards of efficacy and safety, yet Ireland lags behind in adoption rates compared to other EU countries [22]. Overcoming barriers such as prescriber and patient perceptions, supporting substitution policies, and reducing wastage are vital steps [45]. Strategies like an "opt out" substitution model and feedback to prescribers on non-substitution costs could drive change, alongside integrating the patient voice as seen in the “Choosing Wisely” campaigns [35, 39, 48]. Legislative reform allowing pharmacist substitution of biosimilars, when clinically appropriate, could further aid this transition [14] Table 1). Reallocating cost savings to enhance patient access and equity would create a more sustainable healthcare system with better outcomes for patients and the broader health economy. Table 1Recommendations to Optimise Biosimilar Adoption in Medical Oncology in IrelandDomainRecommendations1. Policy & RegulationConsider introducing legislative reform permitting pharmacist-led substitution of biosimilars where clinically appropriateConsider implementing an “opt-out” biosimilar substitution model to encourage routine adoptionStrengthen oversight of patent protections, including addressing patent thickets and high-cost subcutaneous formulations that delay market competitionAlign with emerging EMA/MHRA streamlined biosimilar approval pathways based primarily on analytical and pharmacokinetic evidence2. Procurement & System ManagementUtilise multi-winner tendering with transparent award criteria to support competition and reduce costsProvide prescribers with regular feedback on the cost implications of non-substitution3. Clinical Practice & Prescriber EducationStrengthen clinician education programmes addressing biosimilar safety, efficacy, and interchangeabilityDevelop standardised switching protocols consistent with ASCO and EMA guidancePromote shared decision-making tools to support clinicians and patients during biosimilar transitions4. Patient Engagement & CommunicationEmbed Patient and Public Involvement (PPI) contributors in biosimilar policy development and implementationEnhance availability of clear, accessible patient information resources through the HSELeverage “Choosing Wisely”-style initiatives to promote understanding of sustainable and appropriate biologic use5. Cost Optimisation & Health System SustainabilityReduce drug wastage by optimising dosing schedules, vial use, and administration routesReinvest savings generated through biosimilar adoption to expand equitable access to oncology biologicsIntegrate biosimilar adoption within broader oncology cost-optimisation frameworks, including dose optimisation and avoidance of low-value treatmentsUse real-world evidence to monitor outcomes and inform continuous improvement Table 1Recommendations to Optimise Biosimilar Adoption in Medical Oncology in IrelandDomainRecommendations1. Policy & RegulationConsider introducing legislative reform permitting pharmacist-led substitution of biosimilars where clinically appropriateConsider implementing an “opt-out” biosimilar substitution model to encourage routine adoptionStrengthen oversight of patent protections, including addressing patent thickets and high-cost subcutaneous formulations that delay market competitionAlign with emerging EMA/MHRA streamlined biosimilar approval pathways based primarily on analytical and pharmacokinetic evidence2. Procurement & System ManagementUtilise multi-winner tendering with transparent award criteria to support competition and reduce costsProvide prescribers with regular feedback on the cost implications of non-substitution3. Clinical Practice & Prescriber EducationStrengthen clinician education programmes addressing biosimilar safety, efficacy, and interchangeabilityDevelop standardised switching protocols consistent with ASCO and EMA guidancePromote shared decision-making tools to support clinicians and patients during biosimilar transitions4. Patient Engagement & CommunicationEmbed Patient and Public Involvement (PPI) contributors in biosimilar policy development and implementationEnhance availability of clear, accessible patient information resources through the HSELeverage “Choosing Wisely”-style initiatives to promote understanding of sustainable and appropriate biologic use5. Cost Optimisation & Health System SustainabilityReduce drug wastage by optimising dosing schedules, vial use, and administration routesReinvest savings generated through biosimilar adoption to expand equitable access to oncology biologicsIntegrate biosimilar adoption within broader oncology cost-optimisation frameworks, including dose optimisation and avoidance of low-value treatmentsUse real-world evidence to monitor outcomes and inform continuous improvement Recommendations to Optimise Biosimilar Adoption in Medical Oncology in Ireland Consider introducing legislative reform permitting pharmacist-led substitution of biosimilars where clinically appropriate Consider implementing an “opt-out” biosimilar substitution model to encourage routine adoption Strengthen oversight of patent protections, including addressing patent thickets and high-cost subcutaneous formulations that delay market competition Align with emerging EMA/MHRA streamlined biosimilar approval pathways based primarily on analytical and pharmacokinetic evidence Utilise multi-winner tendering with transparent award criteria to support competition and reduce costs Provide prescribers with regular feedback on the cost implications of non-substitution Strengthen clinician education programmes addressing biosimilar safety, efficacy, and interchangeability Develop standardised switching protocols consistent with ASCO and EMA guidance Promote shared decision-making tools to support clinicians and patients during biosimilar transitions Embed Patient and Public Involvement (PPI) contributors in biosimilar policy development and implementation Enhance availability of clear, accessible patient information resources through the HSE Leverage “Choosing Wisely”-style initiatives to promote understanding of sustainable and appropriate biologic use Reduce drug wastage by optimising dosing schedules, vial use, and administration routes Reinvest savings generated through biosimilar adoption to expand equitable access to oncology biologics Integrate biosimilar adoption within broader oncology cost-optimisation frameworks, including dose optimisation and avoidance of low-value treatments Use real-world evidence to monitor outcomes and inform continuous improvement